中国肺癌杂志2013，Vol.16Issue(4)：203-210,8.DOI:10.3779/j.issn.1009-3419.2013.04.06
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
摘要
Abstract
Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot. Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. Methods Data of 66 EGFR mutant NSCLC patients who were included in Guangzhou medical insurance were analyzed. The efficacy and adverse reactions were evaluated. All the patients were followed-up regularly and the cost of the treatment was recorded. Results The median progression free survival (PFS) of all patients was 15.0 months. 49 patients received gefintib and 17 patients had erlotinib. The PFS for the two groups of patients was 17.5 month and 13 months, respectively (P=0.459). 31 (62.3%) patients had rash in gefitinib group, 16 (94.1%) in erlotinib group. Cost-effectiveness ratio (CER) in gefitinib group was 3,027 RMB per month, while 6,800 RMB in erlotinib group. The incremental cost-effectiveness ratio (ICEA) of erlotinib was 2.25 times of gefitinib. Conclusion For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. The adverse reaction was milder in gefitinib group than that of erlotinib group. And with Guangzhou medical insurance, gefitinib had a superior cost-effectiveness ratio.关键词
吉非替尼/厄洛替尼/肺肿瘤/成本效益分析Key words
Gefitinib/Erlotinib/Lung neoplasms/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
马宇翔,黄岩,赵洪云,刘俊玲,陈丽昆,吴海鹰,周宁宁..晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析[J].中国肺癌杂志,2013,16(4):203-210,8.基金项目
本研究受广东省卫生厅基金(No.A2011203)资助 （No.A2011203）
